Objective: To evaluate the outcome of a novel virtual diabetes clinic on glycemic control in a diverse group of patients with type 2 diabetes.

Methods: 86 patients completed a medical questionnaire, which generates recommendations based on clinical algorithms. All participants had at least one physician consult and unlimited access to a virtual care team (RDs, RN, and PharmD). Participants self-identify race, insurance status, prior conditions and medications. HbA1c levels were documented when joining the program (patient-reported from prior lab or an initial result obtained as part of the program). Subsequent HbA1c results were measured through the lab program (dried blood spot or in-home phlebotomy) or were confirmed results from a non-integrated lab. We compared the first and last HbA1c levels using a paired t-test. In addition, we evaluated the percentage of participants whose HbA1c levels were lowered to target (from >7% to ≤7%).

Results: Participants were highly diverse, with 45.4% self-identifying as non-white. During the study period, 21 of 86 participants received at least one new generic medication or dose adjustment. Among the 24 patients (27.9%) with an initial HbA1c >8%, there was a significant improvement in HbA1c (mean decline 1.7, from 9.5% to 7.8%, p<0.01). Upon joining the program, 39 (45%) participants had an HbA1c >7%; at the end of the study period (ave. 148 days), only 24 (27.9%) had an HbA1c >7% (p=0.018, X2-test).

Conclusions: Participation in a virtual diabetes clinic improved HbA1c significantly over a 3-6 month period in a racially and ethnically diverse population. Prospective studies are needed to confirm the initial effectiveness of a virtual clinic for diabetes over longer periods. Approximately 50% of program members are uninsured and pay an affordable monthly fee. This initial effectiveness suggests that affordable cash-pay virtual clinic solutions may be an efficient and convenient option for patients with diabetes who experience barriers to accessing traditional care.

Disclosure

A.C.Waring: Employee; 9amHealth. B.Schandl: Employee; mySugr, Roche Diabetes Care, Stock/Shareholder; Boydsens, 9amHealth Inc. L.Heinemann: Consultant; 9am.health. M.Hofner: Consultant; 9amHealth Inc. P.Geevarghese: Employee; 9amHealth, Roche Diabetes Care.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.